Mammoth Biosciences
Mammoth Biosciences is a biotechnology company co-founded by Nobel laureate Jennifer Doudna that develops one-time gene-editing treatments for serious genetic diseases.
Analytics date: 29.10.2026
Basic information
Head office
1000 Marina Blvd., Brisbane, CA 94005, USAHead officeGeography of business
United States of America- United Arab Emirates
Geography of businessDate of the last round
Last round 12/2025Date of the last roundTotal funds raised
$379.2M+Total funds raisedPrice per share
$13.45Price per sharePrice per share. Based on the latest known transaction. It is not an offer or investment recommendation.
Analytics date: 29.10.2026
IPO Forecast
Mammoth Biosciences has not announced plans for an IPO, and its executives have not discussed a listing timeline publicly. When the company crossed a $1 billion valuation in 09/2021, it did not respond to questions about going public, with CEO Trevor Martin saying its priority was getting its technology to patients as quickly as possible. In 03/2022, co-founder Janice Chen told CNBC that the founders aimed to build Mammoth into a $100 billion independent company rather than sell it. After the 04/2024 Regeneron deal, Martin said the capital left the company in a strong financial position, with no immediate need to raise more money.
Request price information
Competitor Analysis
Comparison with other companies in the industry.
| Name | Valuation |
| Private companies | |
Isomorphic Labs | 00000 |
Ultima Genomics | 0000 |
Colossal Biosciences | 00000 |
Varda Space Industries | 00000 |
| Traded companies | |
Recursion Pharmaceuticals | 000 |
Schrödinger | 0000 |
Relay Therapeutics | 00000 |
Scribe Therapeutics | 00000 |
Metagenomi Therapeutics | 000 |